Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

The Impact of Volume Overload on Obstructive Sleep Apnea in Patients With Congestive Heart Failure

19 mai 2026 mis à jour par: Itshak Amsalem

The goal of this observational study is to learn how removing extra fluid from the body (diuresis) affects sleep apnea in adults hospitalized with heart failure.

The main questions it aims to answer are:

Does sleep apnea severity improve after fluid removal? Is the improvement in sleep apnea related to the amount of fluid removed? Do changes in neck size reflect changes in sleep apnea severity?

Participants admitted to the hospital with heart failure and fluid overload will take part in this study.

Participants will:

Use a wearable sleep monitoring device (WatchPAT) on the first night of hospitalization Use the device again after fluid removal, when the treating cardiologist determines that the patient is no longer fluid overloaded Have their neck circumference measured before and after fluid removal Have their weight and fluid balance recorded during hospitalization Have routine blood tests and clinical assessments as part of standard care

Researchers will compare each participant's results before and after fluid removal to see if sleep apnea improves and whether these changes are linked to fluid removal and changes in neck circumference.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Type d'étude

Observationnel

Inscription (Estimé)

50

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Itshak Amsalem, MD
  • Numéro de téléphone: +972508229454
  • E-mail: itshak1a@gmail.com

Lieux d'étude

  • Israël
      • Jerusalem, Israël
        • Recrutement
        • Shaare Zedek Medical Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Adults admitted with decompensated heart failure and clinical fluid overload, including both preserved and reduced ejection fraction. Participants will be recruited during hospitalization in a dedicated heart failure unit and followed prospectively with sleep monitoring and clinical assessments before and after achievement of clinical euvolemia.

La description

Inclusion Criteria:

  • Adults aged 18 years or older
  • Hospitalized with decompensated heart failure and clinical evidence of fluid overload
  • Diagnosis of heart failure (reduced or preserved ejection fraction)
  • Clinically indicated for diuretic therapy
  • Able to undergo sleep apnea assessment using the WatchPAT device
  • Able to provide informed consent

Exclusion Criteria:

  • Known central sleep apnea as the predominant sleep-disordered breathing type
  • Current treatment with continuous positive airway pressure (CPAP)
  • Acute respiratory failure requiring mechanical ventilation
  • Conditions preventing proper use of the WatchPAT device (e.g., severe hand or finger injury)
  • Hemodynamic instability precluding participation
  • Pregnancy

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Cohortes et interventions

Groupe / Cohorte
Adults With Heart Failure Undergoing Diuresis
Adults hospitalized with heart failure and fluid overload who undergo standard diuretic therapy. Participants are evaluated using sleep monitoring (WatchPAT), neck circumference measurements, and clinical assessments before diuresis (on the first night of hospitalization) and after diuresis, when the treating cardiologist determines that the patient is no longer fluid overloaded.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in apnea-hypopnea index (AHI)
Délai: From first night of hospitalization to achievement of clinical euvolemia (during hospitalization), up to 30-days.
Change in obstructive sleep apnea severity, measured by the apnea-hypopnea index (AHI) using the WatchPAT device, between the first night of hospitalization (pre-diuresis) and after diuresis, when the treating cardiologist determines that the participant is no longer fluid overloaded
From first night of hospitalization to achievement of clinical euvolemia (during hospitalization), up to 30-days.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in oxygen desaturation index (ODI)
Délai: From first night of hospitalization to achievement of clinical euvolemia, up to 30-days.
Change in oxygen desaturation index (ODI) measured by the WatchPAT device between pre-diuresis and post-diuresis assessments
From first night of hospitalization to achievement of clinical euvolemia, up to 30-days.
Change in respiratory disturbance index (RDI)
Délai: From first night of hospitalization to achievement of clinical euvolemia, up to 30-days.
Change in respiratory disturbance index (RDI), defined as the number of respiratory disturbance events per hour of sleep, measured using the WatchPAT device, between the first night of hospitalization (pre-diuresis) and after diuresis, when the treating cardiologist determines that the participant is no longer fluid overloaded
From first night of hospitalization to achievement of clinical euvolemia, up to 30-days.
Correlation between change in respiratory disturbance index (RDI) and body weight change
Délai: From first night of hospitalization to achievement of clinical euvolemia, up to 30-days.
Correlation between the change in respiratory disturbance index (RDI), measured in events per hour using the WatchPAT device, and change in body weight measured in kilograms during hospitalization
From first night of hospitalization to achievement of clinical euvolemia, up to 30-days.
Correlation between change in apnea-hypopnea index (AHI) and body weight change
Délai: From first night of hospitalization to achievement of clinical euvolemia, up to 30 days
Correlation between the change in apnea-hypopnea index (AHI), defined as the number of apnea and hypopnea events per hour of sleep and measured using the WatchPAT device, and change in body weight measured in kilograms during hospitalization
From first night of hospitalization to achievement of clinical euvolemia, up to 30 days
Change in neck circumference
Délai: From admission to achievement of clinical euvolemia, up to 30 days
Change in neck circumference, measured in centimeters using a standardized measuring tape, between pre-diuresis (at admission) and post-diuresis assessment after the treating cardiologist determines that the participant is no longer fluid overloaded
From admission to achievement of clinical euvolemia, up to 30 days
Correlation coefficient between change in neck circumference and change in apnea-hypopnea index (AHI)
Délai: From admission to achievement of clinical euvolemia, up to 30 days
Correlation coefficient (unitless) describing the relationship between change in neck circumference (centimeters) and change in apnea-hypopnea index (AHI), measured in events per hour using the WatchPAT device
From admission to achievement of clinical euvolemia, up to 30 days

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Itshak Amsalem

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 janvier 2026

Achèvement primaire (Estimé)

1 janvier 2027

Achèvement de l'étude (Estimé)

1 juin 2027

Dates d'inscription aux études

Première soumission

15 avril 2026

Première soumission répondant aux critères de contrôle qualité

19 mai 2026

Première publication (Réel)

22 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

22 mai 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

19 mai 2026

Dernière vérification

1 avril 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • 0350-24-SZMC

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Description du régime IPD

Individual participant data (IPD) sharing is currently undecided. Any future data sharing will depend on institutional policies, ethical approvals, and applicable data protection regulations. If shared, only de-identified data will be made available to qualified researchers upon reasonable request.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner